Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16318447 | 0.93 | KDM4E (0.52) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL3677780 | 0.84 | XDH (0.54) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL11959276 | 0.84 | LCK (0.49) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL2934675 | 0.84 | CA12 (0.54) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL10318265 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL31359219 | 0.83 | NOTUM (0.51) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL31480211 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL4516629 | 0.83 | MAPT (0.55) | KDM4EALDH1A1HPGDATMGLA | |
| SCHEMBL31104508 | 0.83 | MAPT (0.50) | KDM4EALDH1A1HPGDGAAPDK1 | |
| SCHEMBL11959263 | 0.83 | MAPT (0.50) | KDM4EALDH1A1HPGDGAAPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | KDM4E 3395/4885ALDH1A1 451/4885HPGD 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.